Novo’s CEO Doesn’t Seem To Mind Being Big Pharma’s Villian
Novo Nordisk, under new CEO Maziar Mike Doustdar, has a new attitude. It’s making Pfizer livid.
Novo’s CEO Doesn’t Seem To Mind Being Big Pharma’s Villian Read More »
HRSA approves 340B rebate models to hospitals’ chagrin
Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara and Novo Nordisk’s Novolog.
HRSA approves 340B rebate models to hospitals’ chagrin Read More »
iPhone 16 Pro: ¿Conviene comprarlo ahora o esperar el iPhone 17?
Con la llegada del iPhone 17 al mercado, muchas personas se preguntan si vale la pena invertir en el iPhone 16 Pro actual o esperar por las nuevas funcionalidades. Esta decisión se vuelve especialmente relevante considerando que el iPhone 16 Pro fue anunciado el 9 de septiembre de 2024 y lanz …
iPhone 16 Pro: ¿Conviene comprarlo ahora o esperar el iPhone 17? Read More »
¿Cuánto cuesta un reloj inteligente actualmente?
Saber cuánto cuesta un reloj inteligente no es solo mirar la etiqueta: el precio cambia según sensores de salud, autonomía, materiales, compatibilidad y funciones como llamadas, notificaciones o pagos. Pexels En esta nota encontrarás rangos de …
¿Cuánto cuesta un reloj inteligente actualmente? Read More »
Few health systems report significant ROI from virtual care: survey
Fewer than 30% of health system leaders said they earned significant return on investment from virtual care offerings, according to the report by Sage Growth Partners.
Few health systems report significant ROI from virtual care: survey Read More »
Dexcom execs say company has fixed G7 quality problems
After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving customer service has also been a focus for the company.
Dexcom execs say company has fixed G7 quality problems Read More »
4DMT Sends Eye Disease Asset’s Asia Rights to Otsuka for $85M Upfront
Otsuka Pharmaceuticals could shell out over $400 million in total for the Asia-Pacific rights to 4D-150, which combines a VEGF-C inhibitory RNAi with Regeneron’s Eylea into a single ocular injection.
4DMT Sends Eye Disease Asset’s Asia Rights to Otsuka for $85M Upfront Read More »
New CBO report confirms 340B’s ballooning costs. Congress must act.
Former Congressional Budget Office Director Dan Crippen argues the 340B discount program is overdue for reform.
New CBO report confirms 340B’s ballooning costs. Congress must act. Read More »
Lilly Refines Pain Pipeline Again, Scrapping Mid-Stage Program
Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly said that results were not sufficient for advancement of the Asahi Kasei–partnered asset.
Lilly Refines Pain Pipeline Again, Scrapping Mid-Stage Program Read More »
Evommune Joins IPO Class With Planned $160M Raise For Immuno Pipeline
With the shutdown ongoing, Evommune plans to close its IPO on Nov. 5 via a Securities Act clause that allows registrations to come into effect after a certain window has passed.
Evommune Joins IPO Class With Planned $160M Raise For Immuno Pipeline Read More »